NCT06258174View on ClinicalTrials.gov

A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

December 22, 2021

Study Completion Date

December 22, 2021

Conditions

Healthy

Interventions

DRUG

Pirtobrutinib

Administered orally.

Trial Locations (1)

75247

Labcorp Drug Development, Dallas

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06258174 - A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants | Biotech Hunter | Biotech Hunter